Phenotypes associated with this allele

• Allele Symbol: Sftpc⁺
• Allele Name: wild type
• Allele ID: MGI:2434380
• Summary: 14 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
ht1	Sftpc^tm1.1Mfbs/Sftpc^+	B6.Cg-Sftpc^tm1.1Mfbs	MGI:6740368
ht2	Sftpc^tm2.1Mfbs/Sftpc^+	B6.Cg-Sftpc^tm2.1Mfbs	MGI:8407099
ht3	Sftpc^tm1.1Xft/Sftpc^+	Not Specified	MGI:8405103
cn4	Sftpc^tm2Mfbs/Sftpc^+ Gt(ROSA)26Sor^tm1(cre/ERT2)Tyj/Gt(ROSA)26Sor^+	B6.Cg-Gt(ROSA)26Sor^tm1(cre/ERT2)Tyj Sftpc^tm2Mfbs	MGI:8407104
cn5	Sftpc^tm1Mfbs/Sftpc^+ Gt(ROSA)26Sor^tm3(CAG-flpo/ERT2)Alj/Gt(ROSA)26Sor^+	B6.Cg-Gt(ROSA)26Sor^tm3(CAG-flpo/ERT2)Alj Sftpc^tm1Mfbs	MGI:8407107
cn6	Met^tm1Sst/Met^tm1Sst Sftpc^tm1(cre/ERT2,rtTA)Hap/Sftpc^+	involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB/N	MGI:6197801
cn7	Emc3^tm1c(EUCOMM)Wtsi/Emc3^tm1c(EUCOMM)Wtsi Sftpc^tm1(cre/ERT2,rtTA)Hap/Sftpc^+	involves: 129 * C57BL/6 * C57BL/6J * C57BL/6N	MGI:8405105
cn8	Kras^tm4Tyj/Kras^+ Sftpc^tm1.1(cre/ERT2)Ptch/Sftpc^+ Trp53^tm1Brn/Trp53^tm1Brn	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB	MGI:5486065
cn9	Kras^tm4Tyj/Kras^+ Sftpc^tm1.1(cre/ERT2)Ptch/Sftpc^+	involves: 129P2/OlaHsd * C57BL/6 * FVB	MGI:5486056
cn10	Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo Pfkfb2^tm1Ntang/Pfkfb2^tm1Ntang Sftpc^tm1(cre/ERT2)Blh/Sftpc^+	involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6	MGI:8329626
cn11	Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo Pfkfb2^tm2Ntang/Pfkfb2^tm2Ntang Sftpc^tm1(cre/ERT2)Blh/Sftpc^+ Stk11^tm1.1Sjm/Stk11^tm1.1Sjm	involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6	MGI:8329627
cn12	Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo Pfkfb2^tm2Ntang/Pfkfb2^tm2Ntang Sftpc^tm1(cre/ERT2)Blh/Sftpc^+	involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6	MGI:8329628
cn13	Kras^tm4Tyj/Kras^+ Sftpc^tm1(cre/ERT2)Blh/Sftpc^+ Trp53^tm5Tyj/Trp53^+	involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6	MGI:5317171
cn14	Ptpra^tm1c(EUCOMM)Hmgu/Ptpra^tm1c(EUCOMM)Hmgu Sftpc^tm1(cre/ERT2)Blh/Sftpc^+	involves: 129S6/SvEvTac * C57BL/6N	MGI:6690444

Genotype
MGI:6740368

ht1

• Allelic Composition: Sftpc^tm1.1Mfbs/Sftpc⁺
• Genetic Background: B6.Cg-Sftpc^tm1.1Mfbs

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

respiratory system

abnormal lung development ( J:267027 )

• lungs at E18.5 show arrested lung morphogenesis in late sacculation

Genotype
MGI:8407099

ht2

• Allelic Composition: Sftpc^tm2.1Mfbs/Sftpc⁺
• Genetic Background: B6.Cg-Sftpc^tm2.1Mfbs

mortality/aging

postnatal lethality, complete penetrance ( J:279196 )

• mice exhibit a median survival of 2.5 days due to lethal postnatal respiratory failure

respiratory system

lung inflammation ( J:279196 )

• lungs exhibit inflammatory infiltrate

abnormal lung morphology ( J:279196 )

• mice exhibit distorted lung architecture, enlargement of airspaces, interstitial widening, and inflammatory infiltrate

• lungs at P2 exhibit heterogenous areas of thickened septae with proteinaceous fluid in the alveolar space

abnormal lung interstitium morphology ( J:279196 )

• lungs exhibit interstitial widening

overexpanded pulmonary alveolus ( J:279196 )

respiratory distress ( J:279196 )

• respiratory distress between P1.5 and P3.5

respiratory failure ( J:279196 )

• mice develop lethal postnatal respiratory failure

immune system

lung inflammation ( J:279196 )

• lungs exhibit inflammatory infiltrate

homeostasis/metabolism

cyanosis ( J:279196 )

• cyanosis between P1.5 and P3.5

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
interstitial lung disease		DOID:3082	OMIM:PS619611	J:279196

Genotype
MGI:8405103

ht3

• Allelic Composition: Sftpc^tm1.1Xft/Sftpc⁺
• Genetic Background: Not Specified

respiratory system

abnormal pulmonary alveolus morphology ( J:376785 )

• mice exhibit subtle airspace enlargement (simplified alveoli)

Genotype
MGI:8407104

cn4

• Allelic Composition: Sftpc^tm2Mfbs/Sftpc⁺; Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/Gt(ROSA)26Sor⁺
• Genetic Background: B6.Cg-Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj} Sftpc^tm2Mfbs

respiratory system

alveolitis ( J:279196 )

• tamoxifen-treated mice develop alveolitis 2 weeks after treatment that is sustained to 4 weeks, although less severely than in homozygous mice

immune system

alveolitis ( J:279196 )

• tamoxifen-treated mice develop alveolitis 2 weeks after treatment that is sustained to 4 weeks, although less severely than in homozygous mice

growth/size/body

growth/size/body region phenotype ( J:279196 )

N • tamoxifen-treated mice do not show weight loss

mortality/aging

mortality/aging ( J:279196 )

N • tamoxifen-treated mice do not show early mortality

Genotype
MGI:8407107

cn5

• Allelic Composition: Sftpc^tm1Mfbs/Sftpc⁺; Gt(ROSA)26Sor^{tm3(CAG-flpo/ERT2)Alj}/Gt(ROSA)26Sor⁺
• Genetic Background: B6.Cg-Gt(ROSA)26Sor^{tm3(CAG-flpo/ERT2)Alj} Sftpc^tm1Mfbs

respiratory system

alveolitis ( J:267027 )

• adult mice administered intraperitoneal tamoxifen develop moderate alveolitis and interstitial histological changes 2 weeks after induction

immune system

alveolitis ( J:267027 )

• adult mice administered intraperitoneal tamoxifen develop moderate alveolitis and interstitial histological changes 2 weeks after induction

mortality/aging

mortality/aging ( J:267027 )

N • tamoxifen-treated mice do not show early mortality

growth/size/body

growth/size/body region phenotype ( J:267027 )

N • tamoxifen-treated mice do not show weight loss

Genotype
MGI:6197801

cn6

• Allelic Composition: Met^tm1Sst/Met^tm1Sst; Sftpc^{tm1(cre/ERT2,rtTA)Hap}/Sftpc⁺
• Genetic Background: involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB/N

respiratory system

abnormal pulmonary alveolus morphology ( J:264185 )

• tamoxifen-treated mice show reduced density of alveoli

overexpanded pulmonary alveolus ( J:264185 )

• alveoli are enlarged in tamoxifen-treated mice

emphysema ( J:264185 )

• adult mice treated with tamoxifen exhibit enlargement of alveolar airspace and loss of alveolar density, indicating emphysematous changes

Genotype
MGI:8405105

cn7

• Allelic Composition: Emc3^{tm1c(EUCOMM)Wtsi}/Emc3^{tm1c(EUCOMM)Wtsi}; Sftpc^{tm1(cre/ERT2,rtTA)Hap}/Sftpc⁺
• Genetic Background: involves: 129 * C57BL/6 * C57BL/6J * C57BL/6N

respiratory system

respiratory system phenotype ( J:376785 )

N • lung morphology is not altered in tamoxifen-treated mice

Genotype
MGI:5486065

cn8

• Allelic Composition: Kras^tm4Tyj/Kras⁺; Sftpc^{tm1.1(cre/ERT2)Ptch}/Sftpc⁺; Trp53^tm1Brn/Trp53^tm1Brn
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB

mortality/aging

decreased tumor-free survival time ( J:195738 )

• many mice do not survive to 13 weeks after tamoxifen treatment due to high tumor burden

• mice display leaky cre expression without tamoxifen treatment and survive a few months longer than tamoxifen-treated animals

neoplasm

increased lung adenoma incidence ( J:195738 )

• after tamoxifen treatment, mice show a more severe phenotype than animals with wild-type Trp53 (greater tumor size, tumor growth and tumor grade); by 3-4 weeks after tamoxifen treatment, several small adenomas of papillary nature are observed in alveoli

• at 10 weeks after tamoxifen injection, many alveoli have large tumors; tumors exhibit enlarged pleomorphic nuclei, aberrant mitosis; tumor giant cells are present

increased lung adenocarcinoma incidence ( J:195738 )

• mice surviving to 13 weeks after tamoxifen treatment have adenocarcinomas in the alveoli of the lungs

• without tamoxifen treatment, mice develop invasive lung adenocarcinomas localized to the alveoli

• bronchioalveolar duct junctions (BADJs) appear normal ( in mice with or without tamoxifen treatment)

respiratory system

increased lung adenoma incidence ( J:195738 )

• after tamoxifen treatment, mice show a more severe phenotype than animals with wild-type Trp53 (greater tumor size, tumor growth and tumor grade); by 3-4 weeks after tamoxifen treatment, several small adenomas of papillary nature are observed in alveoli

• at 10 weeks after tamoxifen injection, many alveoli have large tumors; tumors exhibit enlarged pleomorphic nuclei, aberrant mitosis; tumor giant cells are present

increased lung adenocarcinoma incidence ( J:195738 )

• mice surviving to 13 weeks after tamoxifen treatment have adenocarcinomas in the alveoli of the lungs

• without tamoxifen treatment, mice develop invasive lung adenocarcinomas localized to the alveoli

• bronchioalveolar duct junctions (BADJs) appear normal ( in mice with or without tamoxifen treatment)

increased type II pneumocyte number ( J:195738 )

• 8 days after tamoxifen treatment, extensive type II cell proliferation is observed compared to wild-type; however, proliferating bronchioalveolar stem cells (BASCs) are rarely observed (at 8 days, 3, 6, 10 and 13 weeks after tamoxifen treatment)

• tumor cells express type II cell markers and are highly proliferative, even without tamoxifen treatment

Genotype
MGI:5486056

cn9

• Allelic Composition: Kras^tm4Tyj/Kras⁺; Sftpc^{tm1.1(cre/ERT2)Ptch}/Sftpc⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * FVB

neoplasm

increased lung adenoma incidence ( J:195738 )

• by 18 weeks after tamoxifen treatment, numerous adenomas develop in alveoli; small numbers of cells with features of malignant transformation are observed in some lung sections

• tumors are usually found in proximity to the airways, bronchioalveolar duct junctions (BADJs), or surface of the lung, but lesions are not found in the BADJs

• tumor cells are highly proliferative

• airways and BADJs retain normal architecture

respiratory system

increased lung adenoma incidence ( J:195738 )

• by 18 weeks after tamoxifen treatment, numerous adenomas develop in alveoli; small numbers of cells with features of malignant transformation are observed in some lung sections

• tumors are usually found in proximity to the airways, bronchioalveolar duct junctions (BADJs), or surface of the lung, but lesions are not found in the BADJs

• tumor cells are highly proliferative

• airways and BADJs retain normal architecture

Genotype
MGI:8329626

cn10

• Allelic Composition: Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}; Pfkfb2^tm1Ntang/Pfkfb2^tm1Ntang; Sftpc^{tm1(cre/ERT2)Blh}/Sftpc⁺
• Genetic Background: involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6

cellular

decreased cellular ATP level ( J:353628 )

• reduced glycolytic ATP production in AT2 cells

homeostasis/metabolism

decreased cellular ATP level ( J:353628 )

• reduced glycolytic ATP production in AT2 cells

respiratory system

abnormal pulmonary alveolus epithelial cell morphology ( J:353628 )

• reduced number of AT1 cells 63 days after bleomycin-induced lung injury at age 12 months

• normal number of AT2 cells 63 days after bleomycin-induced lung injury at age 12 months

decreased type I pneumocyte number ( J:353628 )

• 63 days after bleomycin-induced lung injury at age 12 months

pulmonary fibrosis ( J:353628 )

• 63 days after bleomycin-induced lung injury at age 12 months

abnormal vital capacity ( J:353628 )

• reduced forced vital capacity 63 days after bleomycin-induced lung injury at age 12 months

decreased lung compliance ( J:353628 )

• 63 days after bleomycin-induced lung injury at age 12 months

Genotype
MGI:8329627

cn11

• Allelic Composition: Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}; Pfkfb2^tm2Ntang/Pfkfb2^tm2Ntang; Sftpc^{tm1(cre/ERT2)Blh}/Sftpc⁺; Stk11^tm1.1Sjm/Stk11^tm1.1Sjm
• Genetic Background: involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6

homeostasis/metabolism

abnormal susceptibility to injury induced morbidity/mortality ( J:353628 )

• reduced lung fibrosis, better forced vital lung capacity, better lung compliance and increased number of alveolar type I (AT1) cells 63 days after bleomycin-induced lung injury at age 12 months

mortality/aging

abnormal susceptibility to injury induced morbidity/mortality ( J:353628 )

• reduced lung fibrosis, better forced vital lung capacity, better lung compliance and increased number of alveolar type I (AT1) cells 63 days after bleomycin-induced lung injury at age 12 months

Genotype
MGI:8329628

cn12

• Allelic Composition: Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}; Pfkfb2^tm2Ntang/Pfkfb2^tm2Ntang; Sftpc^{tm1(cre/ERT2)Blh}/Sftpc⁺
• Genetic Background: involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6

homeostasis/metabolism

abnormal susceptibility to injury induced morbidity/mortality ( J:353628 )

• reduced lung fibrosis, better forced vital lung capacity, better lung compliance and increased number of alveolar type I (AT1) cells 63 days after bleomycin-induced lung injury at age 12 months

mortality/aging

abnormal susceptibility to injury induced morbidity/mortality ( J:353628 )

• reduced lung fibrosis, better forced vital lung capacity, better lung compliance and increased number of alveolar type I (AT1) cells 63 days after bleomycin-induced lung injury at age 12 months

Genotype
MGI:5317171

cn13

• Allelic Composition: Kras^tm4Tyj/Kras⁺; Sftpc^{tm1(cre/ERT2)Blh}/Sftpc⁺; Trp53^tm5Tyj/Trp53⁺
• Genetic Background: involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6

mortality/aging

premature death ( J:182218 )

• mice die 14 weeks or less after tamoxifen administration

neoplasm

increased lung adenoma incidence ( J:182218 )

• at 6-8 weeks of age, animals administered 1dose or 4 doses of tamoxifen develop widespread adenomas in the alveoli by 14 weeks of age, but the bronchoalveolar duct junction remains tumor-free

increased adenocarcinoma incidence ( J:182218 )

• at 6-8 weeks of age, animals administered 1dose or 4 doses of tamoxifen develop widespread adenocarcinomas in the alveoli by 14 weeks of age

respiratory system

increased lung adenoma incidence ( J:182218 )

• at 6-8 weeks of age, animals administered 1dose or 4 doses of tamoxifen develop widespread adenomas in the alveoli by 14 weeks of age, but the bronchoalveolar duct junction remains tumor-free

abnormal pulmonary alveolus morphology ( J:182218 )

• at 2 weeks after tamoxifen treatement, brochioalveolar duct junctions (BADJ) appear normal, but small adenomas occur in the alveoli; these progress to adenocarcinoma but the BADJ remain histologically normal

Genotype
MGI:6690444

cn14

• Allelic Composition: Ptpra^{tm1c(EUCOMM)Hmgu}/Ptpra^{tm1c(EUCOMM)Hmgu}; Sftpc^{tm1(cre/ERT2)Blh}/Sftpc⁺
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6N

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:300194 )

N • bleomycin, tamoxifen-treated mice develop fibrosis and lung collagen content as in control mice